A landmark study has revealed that women who received the Human Papillomavirus (HPV) vaccine during early adolescence face an almost zero risk of dying from cervical cancer before the age of 30.
The study, published in The Lancet and funded by Cancer Research UK, found a significant decline in cervical cancer deaths among women who were offered the HPV vaccine following its introduction in England in 2008.
Researchers from Queen Mary University of London examined national vaccination and cancer mortality records involving women aged between 20 and 34 years to evaluate the vaccine’s long-term impact on survival rates.
According to the findings, mortality rates remained largely unchanged among women who were never offered the vaccine. However, substantial reductions in cervical cancer deaths were recorded among vaccinated groups.
The researchers estimated that girls who received the vaccine at ages 12 or 13 are now highly unlikely to die from cervical cancer before turning 30. Among vaccinated women aged 30 to 34, the risk of dying from the disease was found to be 63 per cent lower than that of unvaccinated women.
Although previous studies established that the HPV vaccine prevents about 90 per cent of cervical cancer cases, the latest research provides some of the strongest evidence yet of its ability to reduce deaths from the disease.
The World Health Organisation (WHO) ranks cervical cancer as the fourth most common cancer affecting women worldwide. Nearly all cases are linked to high-risk strains of the Human Papillomavirus, with approximately 3,300 women diagnosed annually in England.
Lead author of the study, Professor Peter Sasieni, a cancer epidemiologist at Queen Mary University of London, described the results as a remarkable public health achievement.
He said, “We estimate that since the introduction of the HPV vaccination programme, nearly 200 young women in England have been saved from dying of cervical cancer.”
Beyond cervical cancer, the vaccine also offers protection against several other HPV-related diseases, including cancers of the anus, penis, vagina, vulva, mouth and throat, as well as genital warts.
The findings come amid growing concerns over declining vaccination rates in some areas. Under the WHO’s global strategy to eliminate cervical cancer, 90 per cent of girls are expected to be fully vaccinated against HPV by the age of 15 by 2030.
Professor Sasieni noted that the high vaccination coverage achieved among women born between 1995 and 2004 could prevent thousands more cervical cancer deaths in the years ahead.
“HPV vaccination, combined with regular cervical screening, has the potential to reduce cervical cancer to the point where it becomes exceedingly rare,” he said.
However, he warned that falling vaccination uptake could undermine the progress already made.
“The decline in HPV vaccine coverage means that without urgent and coordinated efforts to improve uptake, these gains could be reversed,” he cautioned.
Reacting to the findings, President of the Royal College of Obstetricians and Gynaecologists, Dr Alison Wright, described the study as both “exciting and powerful,” saying it demonstrates the vaccine’s ability not only to prevent cervical cancer diagnoses but also to save lives.
Health officials in the National Health Service (NHS) also said the results reinforce the life-saving value of the HPV vaccination programme and support ongoing efforts to eliminate cervical cancer as a major public health threat.